O steoporotic hip fractures are common and disabling and identify a group of older Americans who are at high risk for future fractures. Of the estimated 300,000 cases of hip fracture in the United States annually, 1 one in four will require long-term nursing home care, 2, 3 and one in five will die in the year after fracture. 4 Hip fractures are also a potent risk factor for future fractures. Patients who suffer a hip fracture are 2 to 4 times as likely to have a recurrent hip fracture, with 10% having another fracture within 1 year. 5 Although guideline-recommended osteoporosis treatment 2, 3 with a combination of calcium, vitamin D (Cal1D), and antiresorptive drugs can dramatically reduce fracture risk by up to 50%, [6] [7] [8] rates of treatment after hip fracture are low. [9] [10] [11] [12] Previous studies have shown higher rates of osteoporosis treatment using multidisciplinary in-hospital consultations and case managers to encourage outpatient primary care physicians to initiate treatment, [13] [14] [15] [16] [17] [18] [19] but these interventions have not been widely adopted, resulting in continuing low rates of osteoporosis treatment.
One intervention that may improve osteoporosis treatment rates is the in-hospital initiation of osteoporosis medications for patients with hip fracture. 15, 16, 18, 20 Studies of acute coronary syndromes and heart failure have found that in-hospital initiation of medications improves longterm adherence and mortality. 22, 23 Furthermore, in-hospital pneumococcal vaccination and smoking cessation counseling highlight the effectiveness of using the hospital setting to identify and initiate treatment for high-risk populations. 24, 25 Hospitalization for hip fracture may represent a similar opportunity to identify high-risk patients with osteoporosis and initiate treatment. [13] [14] [15] [16] [17] [18] [19] [20] Because previous studies have generally focused on the outpatient initiation of osteoporosis treatment, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] the rates of in-hospital initiation of osteoporosis treatment after hip fracture are unknown.
The objective of the current study was to examine rates of in-hospital treatment with Cal1D in a large, national cohort of patients hospitalized for osteoporotic hip fractures and identify factors associated with nontreatment. Rates and predictors of treatment with antiresorptive and bone-forming medications, including bisphosphonates, estrogen, raloxifene, teriparatide, and calcitonin, were also examined.
METHODS

Setting and Subjects
A total of 53,325 patients aged 65 and older were admitted to 318 hospitals between October 2003 and September 2005 with a diagnosis of a femoral fracture and had a procedure to correct the fracture as defined according to International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes. Patients were excluded if they sustained a nonfragility fracture associated with significant trauma, such as a motor vehicle accident (n 5 754) or if they had a secondary diagnosis associated with altered calcium metabolism that would contraindicate the receipt of Cal1D supplements, including end-stage renal disease requiring peritoneal or hemodialysis (n 5 801), or conditions associated with hypercalcemia, including hyperparathyroidism, nephrolithiasis, sarcoidosis, and multiple myeloma (n 5 348). Patients were also excluded if they were receiving palliative care (n 5 76), resulting in the final analytical cohort of 51,346 patients. ICD-9-CM codes used to define the patient population are detailed in Figure 1 .
Hospitals in the current study participated in Perspective (Premier Inc., Charlotte, NC), a fee-supported database developed to monitor the clinical and financial aspects of hospital operations. Participating hospitals represent all regions of the United States, are predominantly small to midsized nonteaching facilities, and serve a largely urban patient population. In addition to the clinical and demographic information available in the standard hospital discharge file, the Perspective database contains a datestamped log of all billed items for each patient, including medications and laboratory, diagnostic, and therapeutic services. Because Premier is a group purchasing organization that provides hospitals with supplies, including medications, there is a strong incentive for individual hospitals to capture and relay all pharmacy charges to the Perspective database, resulting in a remarkably complete database that has been successfully used in previous research. 26, 27 Outcome Measures The primary outcome was the in-hospital receipt of at least 100 mg of elemental calcium and 200 IU of vitamin D any time after the procedure to correct the fracture. The secondary outcome was the receipt of antiresorptive or bone-forming osteoporosis medications. Receipt of any one of 35 generic or brand-name osteoporosis medications (bisphosphonates, estrogen and selective estrogen receptor modulators, calcitonin, or teriparatide) any time after hip fracture surgery qualified patients as having received an antiresorptive or bone-forming medication.
Predictor Measures
A variety of factors that might have affected the outcome were examined, including age, sex, ethnicity, and marital status. Comorbidities were accounted for using the Elixhauser method. 29 Admitting source, All Patient Refined Diagnosis Related Group (APR DRG) risk of mortality (Version 15.0, 3M Corporation, Minneapolis, MN), and the specialty of the attending and consulting physicians were obtained from the Perspective discharge file. Internal medicine, family or general medicine, hospital medicine, geriatrics, critical care medicine, and other medicine subspecialties were grouped as medicine providers when considering attending and consulting physicians. In addition to patient-level data, hospital-level covariates were also considered, including each hospital's teaching status, bed size, and geographic region and whether the institution served an urban or rural population.
Statistical Analysis
Age was categorized into 5-year intervals up to age 90. The group aged 80 to 84 was the largest group and was thus used as the reference group. Other factors were coded as dichotomous (e.g., sex) or nominal (e.g., race or ethnicity) variables. Association between predictors and the outcome was first characterized using univariate logistic regression. Multivariate results were obtained using alternating logistic models 30 (SAS proc genmod), which accounted for the clustering of patients within physicians and physicians within hospitals to be accounted for. Variables were selected for inclusion in models based on the level of association with the outcome of interest, because of observed confounding, or to maintain face validity of the model.
To test the robustness of the findings, the analysis was repeated using alternate outcome measures, including the receipt of Cal1D and other osteoporosis medications at any point during the hospitalization and in the last 3 days of hospital stay. Also, given recent research suggesting that older patients who suffer a traumatic fracture are at equally high risk for osteoporosis and adverse outcomes, 31 the analyses were repeated including the 754 subjects who suffered a traumatic fracture. Results from these analyses were similar to the primary analysis, so only the primary results are shown. Additionally, to gauge the completeness of the pharmacy records, the receipt of deep vein thrombosis (DVT) prophylaxis (dalteparin, enoxaparin, fondaparinux, heparin, and warfarin) and antibiotic prophylaxis (53 antibiotics) on the day of surgery and postoperative Day 1 was measured.
All analyses were performed using SAS version 9.1 (SAS Institute, Inc., Cary, NC). The Committee on Human Research at the University of California at San Francisco approved the study.
RESULTS
Patient Characteristics
Fifty-one thousand three hundred forty-six patients aged 65 and older had a procedure to correct a femoral fracture between October 2003 and September 2005 (Table 1) . Most were female, white, and aged 75 and older. Sixty-eight percent had a medicine attending provider or a medicine consultation. Common comorbidities in the cohort were hypertension (65%), chronic pulmonary disease (21%), congestive heart failure (18%), and depression (11%). Most patients received care at nonteaching hospitals in the south; 31.0% of patients received care at large hospitals with more than 500 beds.
Rates of Treatment with Cal1D or Antiresorptive or Bone-Forming Medications Three thousand four hundred five patients (6.6%) received Cal1D any time after procedure to correct femoral fracture; 3,763 patients (7.3%) received an antiresorptive or bone-forming medication, such as a bisphosphonate, estrogen, raloxifene, teriparatide, or calcitonin ( Figure 2 ). Only 1,023 patients (2.0%) were prescribed ideal therapy, receiving Cal1D and another medication for osteoporosis. In contrast to the low rates of osteoporosis medications, 84% of patients received perioperative antibiotic prophylaxis, and 74% of patients received DVT prophylaxis. The rates of DVT and antibiotic prophylaxis were high and similar to those in prior studies, 32 arguing against substantial omissions in the Perspective pharmacy records data.
Predictors of Treatment with Cal1D
Rates of Cal1D administration were less than 8% for virtually all patient-, provider-, and hospital-level characteristics (Table 2) . Rates were less than 8% in all age groups and all APR DRG mortality risk groups. Rates were less than 9% for all types of providers, all geographic regions, and all hospital sizes. Only prescription of an antiresorptive or bone-forming medication was associated with a substantially higher rate of Cal1D administration (27%).
Being male was associated with worse odds of receiving Cal1D (adjusted odds ratio (AOR) 5 0.58, 95% confidence interval (CI) 5 0.52-0.65), as was being black (AOR 5 0.66, 95% CI 5 0.54-0.83). Odds of receiving Cal1D did not differ according to age group, APR DRG mortality risk group, provider, or hospital size.
Predictors of Treatment with Any Other Osteoporosis Medication
Rates of treatment with antiresorptive and bone-forming medications were similar to Cal1D rates and were less than 9% for virtually all patient-, provider-, and hospital-level characteristics (Table 3) . Rates were less than 8% in all age groups and all APR DRG mortality risk groups. Rates were less than 9% for all types of providers, all geographic regions, and all hospital sizes. Only prescription of Cal1D was associated with a substantially higher rate of administration of another osteoporosis medication (30%).
Being male was again associated with worse odds of receiving an antiresorptive or bone-forming medication (AOR 5 0.26, 95% CI 5 0.23-0.29), as was being black (AOR 5 0.68, 95% CI 5 0.55-0.85). Odds of receiving osteoporosis treatment did not differ according to age group, APR DRG mortality risk group, provider, or hospital size.
DISCUSSION
This study showed that rates of osteoporosis treatment for patients hospitalized for hip fracture were low. Rates of treatment with Cal1D were 6.6%, and rates of treatment with antiresorptive or bone-forming medications were 7.3%. Treatment rates were low for virtually all patient-, provider-, and hospital-level characteristics, and the odds of treatment did not differ based on age, risk of mortality, or comorbidities. The strongest predictor of treatment with Cal1D was receipt of an antiresorptive or bone-forming medication (AOR 5 5.50, 95% CI 5 4.84-6.25). Although the relative odds of treatment was much greater, in absolute terms, only 27% of patients who received antiresorptive or bone-forming medications also received Cal1D. Finally, only 2% of patients were prescribed ideal therapy as recommended by current national guidelines, 2,3 receiving Cal1D and an antiresorptive or bone-forming medication for osteoporosis.
Although osteoporosis treatment after hip fracture has traditionally been viewed as an outpatient concern, several factors are focusing more attention on the in-hospital initiation of osteoporosis treatment. First, new medications for osteoporosis such as intravenous (IV) bisphosphonates (approved in 2007 for the treatment of osteoporosis) do not require patients to remain upright and are easier to tolerate in the postoperative period, 6 making in-hospital initiation more practical. Second, prior studies have identified patient adherence to osteoporosis medications as a barrier to treatment, 33, 34 and the once-yearly in-hospital administration of IV bisphosphonates may effectively circumvent this barrier. Third, intervention studies to improve osteoporosis treatment after hip fracture through enhanced outpatient followup have resulted in only modest improvements, 10, 17, 19, 35, 36 suggesting that additional interventions, including in-hospital initiation, may be needed to improve rates of appropriate treatment dramatically. 21 Fourth, the American Orthopedic Association has led the development of the ''Own the Bone'' initiative, which aims to improve the ''treatment of osteoporosis after fragility fracture'' and focuses on hospitalization, recognizing that the ''seriousness of the fracture episode provides physicians with a definite 'teachable moment' in which it is possible to make a major impact on patients' and primary care physicians' behaviors. '' 20,37 Last, the National Osteoporosis Foundation's ''National Action Plan for Bone Health'' focuses on fracture as a sentinel event, stating that, ''Just as a heart attack is seen as a sentinel event for treating cardiovascular disease, a first fragility fracture must be seen as an intervention opportunity. '' 38 Compared with rates of in-hospital lipid diagnosis in cardiovascular patients (81% in 2006) , 38 the low rates of inhospital osteoporosis treatment for hip fracture patients in this study serve as a call to action, as well as a baseline measure for current and future improvement initiatives.
There are several possible explanations for the low rates of in-hospital osteoporosis treatment. First, hospital physicians may be reluctant to address an issue that has traditionally been considered to be an outpatient issue. This may be why the rates in the current study of in-hospital osteoporosis treatment for patients with hip fracture are lower than previously published rates of outpatient osteoporosis treatment. [9] [10] [11] [12] Given the current low rates of appropriate treatment when this issue is deferred to the rehabilitation and outpatient settings, it is likely that the benefits of initiating osteoporosis treatment in the hospital outweigh the risks. Second, Cal1D alone has not been shown to definitively reduce fracture risk, which may lead physicians to discount its role in osteoporosis treatment. 7, 39 However, all osteoporosis treatments rely on adequate intake of Cal1D, and guidelines recommend Cal1D supplementation for all older Americans who have suffered a hip fracture. 2, 3 Third, patients often do not recognize osteoporosis as the underlying cause of their fracture 40, 41 and may be reluctant to start osteoporosis medications in the hospital. Given the many competing acute concerns that need to be addressed during hospitalization, clinicians may find it challenging to educate patients and their families on the importance of osteoporosis treatment.
Finally, concerns remain that bisphosphonates may have a negative effect on fracture healing by disrupting the usual bone remodeling process. Although animal studies have been reassuring, 42 ,43 a recent case-control study found that the risk of humerus fracture nonunion may be greater with outpatient bisphosphonate use, although the absolute rates of nonunion appear to be low. 44 Also, a randomized trial of IV zoledronic acid for the treatment of osteoporosis after hip fracture found no difference in delayed fracture healing or fracture nonunion between subjects receiving zoledronic acid and those receiving placebo, 6 casting doubt on the case-control findings. Thus, even if the bisphosphonate nonunion association is confirmed in cohort studies, it is likely that even small increases in osteoporosis treatment due to in-hospital initiation would outweigh the low absolute risk of nonunion.
Although in-hospital bisphosphonate therapy offers the potential for greater osteoporosis treatment rates, significant practical challenges remain. First, IV bisphosphonates in vitamin D-deficient patients with cancer have led to reports of symptomatic hypocalcemia. 45 Because many patients with hip fracture are deficient in vitamin D, 6 further study is needed to clarify the risks associated with in-hospital IV bisphosphonate therapy for patients with hip fracture. Second, the Medicare inpatient prospective payment system may not reimburse hospitals for additional interventions (such as bone mineral density testing or the administration of IV bisphosphonates) during a hip fracture admission. 46 Thus, there may be a financial disincentive for hospitals to provide this service, even if it is found to be safe and effective. Although these issues need to be addressed for in-hospital administration of IV bisphosphonates, they are not relevant for Cal1D, suggesting that in-hospital initiation of these medications may be a good first step toward improving osteoporosis care in patients with hip fracture.
Although it was found that the rates of osteoporosis treatment were low, certain characteristics were associated with different treatment rates. Consistent with prior studies, the current study found that treatment rates were lower in patient groups at lower baseline risk for osteoporosis, such as men and African Americans, 47, 48 highlighting the importance of educating patients and providers that fragility hip fractures should prompt treatment in all patients.
This study has several limitations. First, information was not available on discharge medications or subsequent outpatient diagnostic or treatment interventions such as bone mineral density testing or initiation of bisphosphonate therapy, and it is probable that some patients were started on osteoporosis treatment after hospitalization. Second, it was not possible to determine which patients were receiving treatment for osteoporosis before hospitalization, and some providers may have assumed that the patient's primary care physician would continue osteoporosis treatment after hospitalization. However, previous studies in the outpatient setting have shown that osteoporosis treatment rates 1 year after hip fracture remain low, with most studies reporting rates below 30%. [9] [10] [11] [12] Third, it is possible that some patients may have had contraindications to treatment, which would suggest that lower treatment rates may be appropriate. Although patients with conditions affecting calcium metabolism were excluded, more-detailed clinical information may have identified more subjects who for whom osteoporosis treatment was inappropriate. However, given the markedly low rates of treatment, it is unlikely that additional clinical information would substantially change the findings. Finally, the measures of Cal1D (100 mg and 200 IU, respectively) are significantly lower than the guideline-recommended amounts. 2 This lower threshold was chosen to minimize the chances that a subject receiving Cal1D would be overlooked. Even with the low threshold, low rates of Cal1D supplementation were found, suggesting that the rates of patients with hip fracture receiving guideline-recommended doses may be even lower.
Strengths of the study include the large, national sample, which captured almost 10% of patients with hip fracture in the United States over a 2-year period.
1 Also, the rates of DVT and antibiotic prophylaxis were similar to previously reported national rates, suggesting that the pharmacy data were reliable and complete. Finally, performing this study in the inpatient setting allowed the rates of Cal1D supplement use to be fully captured. Because Cal1D is over the counter and widely available outside of the hospital, it would have been difficult to objectively capture Cal1D use in the outpatient setting.
In summary, in a national sample of U.S. hospitals, this study found that rates of in-hospital treatment for osteoporosis are low. The results indicate that, despite proven therapies for osteoporosis, patients with hip fracture remain grossly undertreated, placing them at higher risk for future fractures and resultant morbidity and mortality. Future research should focus on identifying barriers and testing interventions to improve rates of in-hospital initiation of guideline-recommended osteoporosis treatment for this vulnerable population.
